*Dear Editor*,

In this Journal, Zheng et al. have report the symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection -named coronavirus disease 2019 (COVID-19)- appear very similar to influenza.[@bib0001] We would like to share our findings for SARS-CoV-2 and influenza virus infections as virus co-circulation is likely to occur in future.[@bib0002] It is important to facilitate differential diagnosis. We therefore conducted a retrospective study to further explore specific features and to better characterize risk factors for severe illness.

This retrospective study included 200 inpatients from the Pitié-Salpêtrière University Hospital (Paris, France) with SARS-CoV-2 (*n* = 100, 'COVID-19 group') or influenza (*n* = 100, 'influenza group') laboratory-confirmed infections on respiratory specimens between January 1st-March 25th, 2020. Patients with complete baseline clinical and biological available data were consecutively included. The study was approved by the Comité Ethique de la Recherche of Sorbonne University (approval number CER 2020--44). Demographic, biological, treatment, and clinical outcome data were extracted from medical records using a standardized form. We collected date of symptom onset, comorbidities, radiographic findings upon admission, and relevant data concerning hospital courses (overall duration of stay, and transfer in intensive care unit \[ICU\] and supportive care ward). Clinical outcomes were monitored up to April 11th, final date of follow-up. Overweight/obesity was defined as body mass index (BMI) \>25 kg/m^2^.

Variables are presented as 'median' (interquartile ranges; IQR) or 'number of' (%). We used the Mann-Whitney U test, χ2 test, or Fisher\'s exact test to compare groups, where appropriate. A two-sided *α*\<0.05 was considered as statistically significant. Risk factors were analyzed by logistic regression analysis. We excluded variables from univariable analysis if their between-group differences were not statistically significant. Variables for multivariable analysis were chosen if *p*\<0.20 in univariable analysis and if the number of events was sufficient to calculate odds ratios (OR). Analyses were performed using GraphPad Prism v.8.

Baseline characteristics of the 200 patients included are shown in the [Table 1](#tbl0001){ref-type="table"} . Overall, the median age was 60 (IQR=50--73; 42 females) and 61 (48--76; 44 females) in COVID-19 and influenza groups, respectively. Comorbidities were present in the majority of patients (\>89%) with diabetes, hypertension, and overweight/obesity as most common comorbidities. However, influenza patients were more likely to have chronic pulmonary diseases (*p* = 0.01). Overweight/obesity rate (*p* = 0.02) and median BMI (*p* = 0.04) were significantly higher in COVID-19. At the time of diagnosis, the most frequent symptoms were fever (*p* = 0.63) and cough (*p* = 1.00) in both groups. COVID-19 patients complained more significantly about fatigue, faintness, diarrhea, and anosmia/ageusia. Conversely, sputum production (*p* = 0.0001) and nasal congestion (*p* = 0.02) were reported most frequently in influenza. The frequency of patients presenting with respiratory failure were similar in both groups (around 10.0%). However, secondary respiratory failure were only observed in COVID-19 (21%; *p*\<0.0001). COVID-19 patients experienced more often acute kidney failure (*p* = 0.048) and pulmonary embolism (*p* = 0.03). Heart congestion was more frequent in influenza (*p* = 0.003). Notably, ground-glass opacities showed a trend towards higher frequency in COVID-19 patients, although not statistically significant (*p* = 0.06). Conversely, pulmonary nodules were much more observed in influenza (*p* = 0.001). Influenza patients had statistically higher levels of white blood cells, neutrophils, platelets, sodium, troponin, albumin than COVID-19 patients ([Table 1](#tbl0001){ref-type="table"}). Both groups exhibited lymphocytopenia (around 80% of patients) (data not shown), however no significant median value difference was observed.Table 1Overall baseline characteristics of patients with COVID-19 or influenza.Table 1COVID-19\# (*n* = 100)Influenza[\#](#tb1fn1){ref-type="table-fn"} (*n* = 100)*p* valueDemographic characteristics Age, median (IQR) -- years60 (50--73)61 (48--76)0.88 Sex -- no. (%)  Female42 (42.0)44 (44.0)0.89  Male58 (58.0)56 (56.0)0.89Occupation -- no. (%)  Active44/96 (45.8)32/85 (37.6)0.29  Health worker4/96 (4.2)4/85 (4.7)1.00  Unemployed16/96 (16.7)13/85 (15.3)0.84  Retired35/96 (36.5)38/85 (44.7)0.29Comorbidity -- no./total no. (%) None10 (10.0)11 (11.0)1.00 Chronic lung disease12 (12.0)27 (27.0)0.01 Cardiovascular disease28 (28.0)30 (30.0)0.88 Chronic renal disease11 (11.0)7 (7.0)0.46 Solid cancer7 (7.0)14 (14.0)0.17 Organ transplant5 (5.0)5 (5.0)1.00 HIV infection1 (1.0)1 (1.0)1.00 HBV infection1 (1.0)1 (1.0)1.00 Pregnancy1 (1.0)1 (1.0)1.00 Hemopathy10 (10.0)13 (13.0)0.66 Neurodegenerative disease3 (3.0)5 (5.0)0.72 Splenectomy2 (2.0)2 (2.0)1.00 Autoimmune and system disease7 (7.0)8 (8.0)1.00CV risk factors -- no./total no. (%) Presence of CV risk factors75/98 (76.5)66 (66.0)0.12 Diabetes24/98 (24.5)16 (16.0)0.16 Dyslipidemia15/98 (15.3)8 (8.0)0.12 Hypertension37/98 (37.8)38 (38.0)1.00 Overweight/obesity40/98 (40.8)25 (25.0)0.02 Obstructive sleep apnea8/98 (8.2)13 (13.0)0.36 Current smoker10/98 (10.2)11 (11.0)1.00 Former smoker15/98 (15.3)18 (18.0)0.70 Chronic alcoholism4/98 (4.1)5 (5.0)1.00BMI[‡](#tb1fn2){ref-type="table-fn"} Median (IQR)27.3 (23.8--32.4)24.8 (21.7--28.6)0.04Symptoms -- no./total no. (%) Fever92 (92.0)89 (89.0)0.63 Fatigue63/99 (63.6)39 (39.0)0.0006 Myalgia36/99 (36.4)24 (24.0)0.06 Dyspnea45 (45.0)51 (51.0)0.48 Cough81 (81.0)80 (80.0)1.00 Productive sputum12 (12.0)36 (36.0)0.0001 Nasal congestion8/96 (8.3)21 (21.0)0.02 Acute respiratory failure31 (31.0)9 (9.0)0.0002  On admission10 (10.0)9 (9.0)1.00  Secondary failure21 (21.0)0\<0.0001 Headache25/99 (25.3)20 (20.0)0.40 Nausea19/97 (19.6)10 (10.0)0.07 Vomiting21/97 (21.6)11 (11.0)0.053 Diarrhea25/97 (25.8)13 (13.0)0.03 Anosmia/ageusia7 (7.0)00.01 Faintness12/99 (12.1)3 (3.0)0.02 Chest pain21 (21.0)16 (16.0)0.47Chest x-rays and CT-findings -- no./total no. (%) Abnormalities on chest radiograph26/36 (72.2)24/49 (49.0)0.04 Bronchial syndrome1/36 (2.8)6/49 (12.2)0.23 Interstitial syndrome11/36 (30.6)2/49 (4.1)0.001 Alveolar syndrome5/36 (13.9)5/49 (10.2)0.74 Lobar consolidation5/36 (13.9)11/49 (22.4)0.41 Abnormalities on CT chest34/34 (100.0)21/22 (95.0)0.39 Ground-glass opacities29/34 (85.3)13/22 (59.1)0.06 Pulmonary nodules3/34 (8.8)11/22 (50.0)0.001 Lobar consolidation16/34 (47.1)11/22 (50.0)1.00Laboratory findings [¤](#tb1fn3){ref-type="table-fn"} (unity; normal range) -- Median (IQR)[§](#tb1fn4){ref-type="table-fn"} White-cell count (G/L; 4.00 -- 10.00)5.88 (4.41--7.68)6.72 (5.15--9.42)0.01 Neutrophils (G/L; 2.00-- 7.50)4.11 (2.99--5.65)5.06 (3.43--7.25)0.02 Lymphocytes (G/L; 1.50--4.00)1.08 (0.68--1.41)0.89 (0.66--1.35)0.41 Hemoglobin (g/dL; 13.0--17.5)13.6 (12.2--14.5)13.2 (11.6--14.3)0.29 Platelets (G/L; 150--400)179 (145--225)199 (168--239)0.04 Fibrinogen (g/L; 2--4)5.5 (4.2--6.7)5.4 (4.5--6.4)0.92 Activated partial thromboplastin time (s; \<1.20)1.16 (1.10--1.30)1.14 (1.04--1.29)0.44 Prothrombin time (%; 70--120)98 (86--100)91 (76--100)0.08 Sodium (U/L; 136--155)137 (135--139)138 (136--140)0.006 Potassium (U/L; 3.4--5.1)4.1 (3.8--4.6)4.0 (3.7--4.4)0.09 Chloride (U/L; 98--107)99 (97--102)100 (97--103)0.35 Bicarbonates (mmol/L; 22 -- 26)24 (22--26)25 (23--27)0.07 Troponin (ng/L; \<0.60)9.2 (6.5--22.4)34.4 (8.8--72.2)0.007 Albumin (g/L; 35--52)30 (27--33)37 (33--39)0.04 C-reactive protein (mg/L; \<5.0)47.37 (15.42--87.46)41.44 (15.25--82.05)0.55 Serum creatinine (µmol/L; 62--106)86 (70--117)87 (70--108)0.75 Total bilirubin (µmol/L; 2--17)8 (5--12)8 (5--12)0.99 Aspartate aminotransferase (U/L; 20--32)45 (34--76)34 (29--49)0.02 Alanine aminotransferase (U/L; 16-- 35)31 (22--59)26 (20--42)0.21 γ -glutamyltransferase (U/L; 12--55)44 (26--101)32 (21--54)0.08 Creatine kinase (U/L; \<190)178 (109--473)117 (65--378)0.42 Lactate dehydrogenase (U/L; 135--215)397 (305--544)298 (248--383)0.04 Arterial lactates (mmol/L; 0.5--1.8)1.0 (0.7--1.4)1.2 (0.9--1.4)0.09 Procalcitonin (µg/L; \<0.10)0.12 (0.08--0.27)0.13 (0.07--0.36)0.74 Arterial blood pH (7.35--7.45)7.45 (7.42--7.48)7.43 (7.40--7.78)0.33Treatments -- no./total no. (%) Oseltamivir11/95 (11.6)45/97 (46.4)\<0.0001 Any antibiotics77/98 (78.6)58/97 (59.8)0.005 Amoxicillin/Clavulanic acid40/98 (40.8)33/97 (34.0)0.37 Cephalosporin48/98 (49.0)21/97 (21.6)\<0.0001 Oxygen therapy65 (65.0)42/99 (42.4)0.002Complications -- no./total no. (%) Pulmonary embolism6 (6.0)00.03 Acute kidney failure17 (17.0)7 (7.0)0.048 Myocarditis02 (2.0)0.50 Heart congestion2 (2.0)14 (14.0)0.003 Heart rhythm disorder7 (7.0)2 (2.0)0.17Clinical outcomes at data cutoff no./total no. (%) Admitted in ICU31 (31.0)12 (12.0)0.002 Discharged75 (80.0)94 (94.0)0.0003 Death20 (20.0)5 (5.0)0.002 Remained in hospital5 (5.0)1 (1.0)0.21[^2][^3][^4][^5]

The median time from illness onset to admission was 4 \[1--6\] and 2 \[0--4\] days for COVID-19 and influenza, respectively (*p* = 0.02, [Fig. 1](#fig0001){ref-type="fig"} ). COVID-19 patients more frequently required hospitalization (*p* = 0.001) (data not shown). Noteworthy, the median duration of overall hospital stay was significantly longer for COVID-19 than for influenza (10 \[4--17\] and 4 \[1--11\] days, respectively, *p*\<0.0001). Overall, COVID-19 patients more frequently required oxygen therapy (*p* = 0.002) ([Table 1](#tbl0001){ref-type="table"}). The median duration between onset of symptoms and aggravation was 7 (5--10) and 4 (2.5--6) days in COVID-19 and influenza groups, respectively (*p*\<0.0001) (data not shown). Clinical worsening was linked to a higher ICU rate admission among COVID patients (*p* = 0.002). Baseline characteristics, clinical courses, outcome, and duration from illness onset concerning severe infections (31 and 12 severe COVID-19 and influenza, respectively) are shown in Supplementary Tables 1--3/[Fig. 1](#fig0001){ref-type="fig"}. Noteworthy, no significant difference was evidenced concerning corticosteroid use comparing both severe infection groups (*p* = 0.84).Fig. 1Duration from illness onset and clinical courses in COVID-19 (*n* = 100) and influenza groups (*n* = 100)Histograms represent duration in days of symptoms before admission (blue), stay out of ICU (light pink), stay in ICU for severe cases (red), and in post-ICU supportive care wards (yellow). *n* represent the number of concerned patients according to type of hospitalization. The median time from illness onset (*i.e.* before admission) to admission was 4 days \[IQR: 1--6\] and 2 days \[IQR: 0--4\] for COVID-19 and influenza patients, respectively (*p* = 0.02). The median time of hospitalization out of ICU was 5 days \[IQR: 1--10\] and 1 day \[IQR: 0--8\] for COVID-19 and influenza patients, respectively (*p* = 0.0112). Overall, 20 and 5 patients died in both groups, respectively. Among ICU-hospitalized patients (31 COVID-19 and 12 influenza), 11 and 3 patients died in both groups, respectively. \* symbolizes significant differences between COVID-19 and influenza groups. COVID-19: coronavirus disease 2019; ICU: intensive care unit. *p*\<0.05 was considered to be statistically significant.Fig 1

In multivariable analysis, odds of severe COVID-19 were significantly higher in individuals with chronic lung disease (OR=6.45; *p* = 0.009), hypertension (3.05; *p* = 0.02), and overweight/obesity (3.23; *p* = 0.02). Obstructive sleep apnea and overweight/obesity were significantly associated with severe influenza in univariable analysis (*p* = 0.04 and *p* = 0.04, respectively) (Supplementary Tables 4--5). The mortality rate was significantly higher in COVID-19 group than in influenza group (20% *vs.* 5%; *p* = 0.002). Age and diabetes appear as death risk factors in COVID-19 in multivariable analysis (OR=1.06 \[95% CI=1.02--1.11\]; *p* = 0.004 and OR=4.50 \[1.48--14.24\]; *p* = 0.009, respectively) (Supplementary Table 6).

To the best of our knowledge, this study is the largest case series to date comparing COVID-19 and influenza. COVID-19 patients more frequently reported dry cough, asthenia, diarrhea, anosmia/ageusia, and clinical worsening around 7 days after symptom onset, as previously described[@bib0003], [@bib0004], [@bib0005], [@bib0006]. As previously reported, radiologic findings showed that ground-glass opacity was more common in COVID-19,[@bib0003] however it could be also observed during influenza.[@bib0005] ^,^ [@bib0006] We reported more severe cases requiring oxygenation therapy, a higher death rate, and a longer hospital stay in COVID-19 group. Moreover, COVID-19 patients also experienced disease aggravation around 7 days post-symptom onset, as previously reported.[@bib0003] ^,^ [@bib0006] Both infection may evolve to respiratory failure,[@bib0003] ^,^ [@bib0005] ^,^ [@bib0006] however, COVID-19 patients developed preferentially secondary respiratory failure. Interestingly, inflammation marker levels were significantly higher in severe COVID-19 cases. It is well established that SARS-CoV-2 triggers an excessive harmful proinflammatory response[@bib0007] promoting thrombotic events as pulmonary embolism.[@bib0008] In our study, pulmonary embolism was only reported during COVID-19 (*p* = 0.03). COVID-19 and influenza patients commonly share overweight/obesity as risk factor for severe infection.[@bib0009] As previously reported, pre-existing hypertension and diabetes were additionally associated with a higher risk to develop severe COVID-19. Similarly, our study also confirmed older age and diabetes as major contributing death risk factors in COVID-19.[@bib0003] ^,^ [@bib0010] To conclude, we described similarities but also differences between COVID-19 and influenza, thereby providing some guidance for healthcare management.
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[^1]: These authors contributed equally to this article.

[^2]: Denominators of patients included in this analysis are shown if they differed from the overall numbers in the respective group.

[^3]: Data regarding BMI medians were available for 56 and 48 patients in COVID-19 and influenza groups, respectively.

[^4]: For each biological variable, the number of digits after decimal point depends on technical precision.

[^5]: Biological data from patients with COVID-19 and Influenza infection were available for hematological values in 100 patients, fibrinogen in 44 and 46 patients, sodium and potassium in 96 and 98 patients, chloride in 96 and 95 patients, bicarbonates in 79 and 85 patients, troponin in 32 and 35 patients, albumin in 7 and 24 patients, C-reactive protein in 64 and 73 patients, serum creatinine in 98 and 98 patients, total bilirubin in 44 and 65 patients, aspartate aminotransferase in 51 and 70 patients, alanine aminotransferase in 51 and 71 patients, ʏ-glutamyltransferase in 48 and 69 patients, creatine kinase in 23 and 34 patients, lactate dehydrogenase in 21 and 34 patients, arterial lactates in 51 and 36 patients, procalcitonin in 60 and 74 patients, arterial blood pH in 48 and 35 patients, respectively.

    BMI: body mass index; COVID-19: coronavirus disease 2019; CT: computed tomography; CV: cardiovascular; HBV: hepatitis B virus; HIV: human immunodeficiency virus; ICU: intensive care unit; IQR: interquartile range; no.: number of. *p*\<0.05 was considered to be statistically significant.
